Skip to main content
SpringerLink
Log in

Trilaciclib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Trilaciclib (Cosela™) is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases (CDK) 4 and 6 developed by G1 Therapeutics for its myeloprotection and potential antitumor efficacy and safety benefits in combination with cancer chemotherapy. CDKs govern cell cycle progression, and trilaciclib induces a transient, reversible G1 cell cycle arrest of proliferating haematopoietic stem and progenitor cells in bone marrow, thus protecting them from damage during chemotherapy. In February 2021, trilaciclib received its first approval in the USA to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). Clinical studies in breast cancer, colorectal cancer and small cell lung cancer are underway in several countries. This article summarizes the milestones in the development of trilaciclib leading to this first approval.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Comprehensive Cancer Network. Small cell lung cancer: NCCN clinical practice guidelines (Version 2.2021). 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed 3 Mar 2021.

  2. Bisi JE, Sorrentino JA, Roberts PJ, et al. Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for eduction of chemotherapy-induced myelosuppression. Mol Cancer Ther. 2016;15(5):783–93.

    Article  CAS  Google Scholar 

  3. Watkins T, Surowiecka MK, McCullough J. Transfusion indications for patients with cancer. Cancer Control. 2015;22(1):38–46.

    Article  Google Scholar 

  4. Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019;30(10):1613–21.

    Article  CAS  Google Scholar 

  5. Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350–65.

    Article  CAS  Google Scholar 

  6. He S, Roberts PJ, Sorrentino JA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017;9(387):1–11.

    Article  Google Scholar 

  7. US FDA. FDA approves drug to reduce bone marrow suppression caused by chemotherapy. [media release]. 12 Feb 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy.

  8. G1 Therapeutics. COSELATM (trilaciclib): US prescribing information. 2021. https://www.g1therapeutics.com/cosela/pi/. Accessed 25 Feb 2021.

  9. G1 Therapeutics. G1 Therapeutics to evaluate trilaciclib (G1T28) in combination with immune checkpoint inhibitor in small-cell lung cancer [media release]. 5 Dec 2016. http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-evaluate-trilaciclib-g1t28-combination-immune.

  10. Quantum Leap Healthcare Collaborative, G1 Therapeutics. Quantum Leap Healthcare Collaborative and G1 Therapeutics announce the selection of trilaciclib in the I-SPY 2 TRIAL for breast cancer [media release]. 14 Jan 2020. http://investor.g1therapeutics.com/news-releases/news-release-details/quantum-leap-healthcare-collaborative-and-g1-therapeutics.

  11. G1 Therapeutics, Boehringer Ingelheim. G1 Therapeutics and Boehringer Ingelheim announce co-promotion agreement for trilaciclib in small cell lung cancer in the United States and Puerto Rico [media release]. 30 Jan 2021. http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-and-boehringer-ingelheim-announce-co-promotion.

  12. G1 Therapeutics. G1 Therapeutics and Simcere announce exclusive license agreement for trilaciclib in Greater China [media release]. 3 Aug 2020. http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-and-simcere-announce-exclusive-license-agreement.

  13. Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2020-000847.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer. 2020. https://doi.org/10.1002/ijc.33453.

    Article  PubMed  Google Scholar 

  15. Weiss J, Goldschmidt J, Zoran A, et al. Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer. J Clin Oncol. 2020;38(15 Suppl):12096.

    Article  Google Scholar 

  16. Beck T, Richards DA, Agajanian R, et al. Trilaciclib has myelopreservation benefits in patients with small cell lung cancer treated with chemotherapy, irrespective of age [abstract no. MO01.40 and poster]. J Thorac Oncol. 2021;16 (1 Suppl):S32–S3.

  17. Hussein M, Gersten TA, Lerro K, et al. Myelopreservation with trilaciclib regardless of risk of chemotherapy-induced febrile neutropenia and/or anemia or red blood cell transfusions [abstract no. MO01.42 and poster]. J Thorac Oncol. 2021;16 (1 Suppl):S33–S4.

  18. Weiss J, Skaltsa K, Gwaltney C, et al. Positive effects of trilaciclib on patient myelosuppression-related symptoms and functioning: results from three phase 2 randomized, double-blind, placebo-controlled small cell lung cancer trials [abstract no. eP723 and presentation]. Support Care Cancer. 2019;27 (1 Suppl):S274–S5.

  19. Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019;20(11):1587–601.

    Article  CAS  Google Scholar 

  20. Subramanian J, Jaal J, Kudaba I, et al. Using an exploratory composite endpoint to evaluate the myelopreservation benefits of trilaciclib in patients with small cell lung cancer [abstract no. MO01.41 and poster]. J Thorac Oncol. 2021;16 (1 Suppl):S33.

  21. G1 Therapeutics. G1 Therapeutics’ COSELA™ (trilaciclib) included in two updated National Comprehensive Cancer Network® (NCCN) clinical practice guidelines in oncology [media release]. 25 Mar 2021. http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-coselatm-trilaciclib-included-two-updated.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Trilaciclib: First Approval. Drugs 81, 867–874 (2021). https://doi.org/10.1007/s40265-021-01508-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01508-y

Search

Navigation